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1. Introduction
Worldwide demand of herbal medicines has increased in recent years owing to rising inter‐
est in the health benefits. Among with this, the quality control of plant extracts and plant-
derived medicines is growing in importance to ensure their efficacy and safety. Effective
quality control of the traditional Chinese medicines (TCM) and plant crude extracts requires
the rapid and sensitive methods for separation and quantification of bioactive compounds.
Various methods have been employed for the separation and quantification of certain con‐
stituents in medicinal plants or herbal medicines. However, the current methods in use are
not necessarily optimal approaches. For example, separation and quantification of glycyrrhi‐
zin (GC), the main active constituent in licorice (Glycyrrhiza spp.), have been used gas chro‐
matography, high performance liquid chromatography (HPLC) and micellar trokinetic
chromatography and so on [1,2]. Commercial purification of GC typically progressed
through several steps, including crystallization, column chromatography, and liquid parti‐
tioning. These current methods are not sufficiently approaches because of insufficient sensi‐
tivity and reproducibility, large consumption of organic solvent for extraction and analysis,
and long analysis time.
Immunoassay systems using monoclonal antibody (MAb) against drugs and small molecu‐
lar  weight  bioactive compounds have become an important  tool  for  studies  on receptor
binding assays, enzyme assays, and quantitative and qualitative analytical techniques both
in vivo and in vitro studies. Although immunoaffinity purification against higher molecule
analyte such as peptides and proteins are widely used in the research and commercial ways,
there  are  too  few cases  of  immunoaffinity  purification  targeting  a  small  molecule  com‐
pound such as natural compounds. Our laboratory has prepared many kinds of MAbs against
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naturally occurring bioactive compounds such as terpenoids [3-5], alkaloids [6,7], saponins
[8-12], and phenolics [13-16], and developed several applications. One of the applications by
using MAbs is immunoaffinity column conjugated with anti-natural compound-specific MAbs
and work by specifically binding and removing the target compounds. We have been estab‐
lishing several affinity columns against a kind of terpenoid, forskolin [17], solasodine glyco‐
sides [18], ginsenosides Rb1 [19], and GC [20]. Application of an immunoaffinity column to
isolate and concentrate a natural compound may decrease the amount of solvent consump‐
tion and the number of purification steps, shorten analysis time, and simplify sample analy‐
sis compared to traditional cleanup techniques.
In this chapter, we focus on the immunoaffinity purification to separate and concentrate the
target bioactive compounds from the crude extract. Our approaches effectively succeeded
one-step  purification  of  target  compounds  by  MAb-conjugated  immunoaffinity  column,
which leads to high-sensitivity detection and isolation of target compounds. In addition, the
immunoaffinity column can prepare the knockout (KO) extract which contains all compo‐
nents except an antigen molecule, and KO extract will be useful for the pharmacological
investigation to reveal the real effects of bioactive compound in the crude extract.The infor‐
mation in this chapter may provide new insight into quality control of plant-derived medicines.
2. Preparation of anti-ginsenoside Rb1 immunoaffinity column and its
application
Ginseng, the root of Panax ginseng, has been an important component in traditional medi‐
cines for more than 1000 years in Eastern Asia. It is now one of the most extensively used
alternative medicines all over the world and appears in the pharmacopoeias of several coun‐
tries. The biological and pharmacological activities of ginseng have been reported to have anti-
aging, anti-cancer, anti-inflammation, anti-diabetics, anti-stress, maintenance of homeostasis,
and to affect on central nervous system and immune function [21]. The bioactive compo‐
nents responsible for ginseng actions are ginsenosides, which are triterpenes saponins that
possess a dammarane skeleton with sugar moieties [22]. Up to now more than 60 kinds of
ginsenosides have been isolated from Panax genus [23]. It is well-known that the concentra‐
tions of ginsenosides vary in the ginseng root or the root extracts depending on the method
of extraction, subsequent treatment, or even the season of its collection [24,25]. Due to the
importance of ginseng, a number of researches has been carried out to develop the methods
for the identification, quantification and quality control of ginsenosides in raw plants materi‐
als, extracts and commercial products. Currently, analytical and preparative HPLC are com‐
monly used to quantify and purify the individual ginsenosides from ginseng [26]. However,
isolation of ginsenosides by HPLC requires the repeated purification steps, including cumber‐
some handling and lengthy analysis times, and may result in the decrease of the final yield.Thus,
the developed approaches are required for quality control of ginseng in the field of TCM.
Ginsenoside Rb1 (G-Rb1) is one of the main ginsenosides responsible for many pharmaceut‐
ical  actions of  ginseng [27].  G-Rb1  has  various biological  activities,  including facilitating
acquisition and retrieval of memory [28], scavenging free radicals [29], inhibition of calci‐
um over-influx into neurons [30], and preserving the structural integrity of the neurons [31].
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In order to develop efficient quality control of ginseng, we have prepared anti-G-Rb1 MAb,
set up of enzyme-linked immunosorbent assay (ELISA), and a new immunostaining meth‐
od named Eastern blotting [8,32]. Furthermore, we established an immunoaffinity column
against G-Rb1 and its application for one-step isolation from crude extract of ginseng root [19,
32]. Herein we describe the preparation of anti-G-Rb1 immunoaffinity column and it appli‐
cations for identification and concentration of G-Rb1.
2.1. Preparation of MAb and immunoaffinity column against G-Rb1
2.1.1. Analytical methodology for determination of hapten number in antigen, hapten-carrier protein
conjugate
The first step for the MAb production is the synthesis of a hapten-carrier protein conjugate.
Bovine serum albumin (BSA) conjugated with G-Rb1 was produced for the preparation of
specific MAb in mouse [8]. There had been no direct and appropriate methods for the deter‐
mination of haptens conjugated carrier proteins without differential UV analysis, radiochem‐
ical or chemical methods. Therefore, immunization by the injection of hapten-carrier protein
conjugate was unreliable. Wengatez et al. determined the hapten density of immuno-conju‐
gates by matrix-assisted UV laser desorption/ionization (MALDI) mass spectrometry [33]. We
also reported the direct analytical method of hapten and carrier protein conjugates by a MALDI
tof mass spectrometry using internal standard [3-16]. Figure 1 shows the MALDI tof mass
spectra of G-Rb1-BSA conjugate. A broad peak coinciding with the conjugate of G-Rb1 and
BSA appeared from m/z 70,000 to 90,000 centering at around m/z 79,469. Using experimental
results and a molecular weight of 66,433 for BSA, the calculated values of G-Rb1component
(MW1,109) are from 3,327 to 23,289 resulting in the range of 3 to 21 (12 in average) mole‐
cules of G-Rb1 conjugated with BSA [8]. This method is suitable for characterization of conju‐
gates between small molecule natural compound and carrier protein conjugates.
Figure 1. Direct detection of G-Rb1-BSA conjugate by MALDI tof mass spectrometry. [M+H]+, [M+2H]2+ are single and
double protonated molecules of G-Rb1-BSA, respectively.
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2.1.2. Preparation of anti-G-Rb1 MAb and ELISA as an assay system
A hybridoma-producing MAb reactive to G-Rb1 was obtained by general procedure and
classified into IgG2b which had κ light chains [8]. The reactivity of IgG type MAb, 9G7 was
tested by varying antibody concentration and by performing a dilution curve. The antibody
concentration was selected for competitive ELISA. The free MAb following competition is
bound to polystyrene microtiter plates precoated with G-Rb1-human serum albumin (HSA).
Under these conditions, the full measurement range of the assay extends from 20 to 400
ng/mL. The cross-reactivity against G-Rc and G-Rd, which possess a diglucose moiety at‐
tached to the C-3 hydroxy group, were weak compared with G-Rb1 (0.024 and 0.020 %, re‐
spectively). G-Re and G-Rg1 showed no cross-reactivity (less than 0.005 %). It is evident that
the MAb reacted only with a small number of structurally related G-Rb1 molecules, and very
weakly and did not react with other steroidal compounds.
2.1.3. Preparation of anti-G-Rb1 immunoaffinity column and appropriate buffer systems for
separation of G-Rb1
The purified IgG (10 mg) was treated by NaIO4 to give dialdehyde group in sugar moiety
which was coupled to Affi-Gel Hz hydrazide gel resulting in a hydrozone-type immunoaf‐
finity gel [32]. The immunoaffinity gel was packed into plastic mini-column (Figure 2). Due
to examine the optimal conditions of adsorption and elution, 400 µg of G-Rb1 was dissolved
in phosphate buffered saline (PBS) and loaded on anti-G-Rb1 affinity column. After washing
with washing buffer (20 mM PB containing 0.5 M NaCl), various buffer solutions for elution
were loaded on the column, and then the recovery efficiency was determined by ELISA. The
G-Rb1 concentration was somewhat increased by eluting with a 20 mM phosphate buffer
containing 0.5 M KSCN and 10 % MeOH. When the 20 mM phosphate buffer was changed
to 100 mM AcOH buffer (pH 4), the elution ability reached the optimal level. Although 20 %
MeOH could enhance the elution of G-Rb1, higher MeOH concentration of over 20 % was
ineffective. Thus, 100 mM AcOH buffer containing 0.5 M KSCN and 20 % MeOH could be
used as an elution buffer in the immunoaffinity chromatography.
Figure 2. Preparation of anti-G-Rb1 immunoaffinity column
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2.2. Purification of G-Rb1 by immunoaffinity column
2.2.1. One-step purification of G-Rb1 from crude extract of P. ginseng roots by anti-G-Rb1immunoaffinity column
A crude extract (3.8 mg) of P. ginseng roots was loaded onto anti-G-Rb1 immunoaffinity col‐
umn. The column was washed with the washing buffer (fractions 1-20), and then eluted
with elution buffer (fractions 21-40). As shown in Figure 3, the fractions 1-8 contained the
overloaded G-Rb1, which determined by ELISA. The other ginsenosides such as G-Rg1, Rc,
Re and Rd were also detected in these fractions by Eastern blotting procedure. After wash‐
ing, a sharp peak was observed around fractions 21-24 of elution buffer, which contained G-
Rb1. However, these eluted fractions were still contaminated by a small amount of malonyl-
G-Rb1 as detected by Eastern blotting. The malonyl-G-Rb1 has almost the same cross-
reactivity with G-Rb1 [32]. Therefore, the eluted fractions were treated with a mild alkaline
solution (0.1 % KOH in MeOH) at room temperature to give pure G-Rb1 [19]. Overcharged
G-Rb1 in washing solution (fractions 1-8) was repeatedly loaded and finally isolated in pure
form. The anti-G-Rb1 MAb was stable during all procedures, and the immunoaffinity col‐
umn showed almost no decrease in capacity (20 µg of G-Rb1/ml gel) after repeated use more
than 10 times under same conditions, as reported for a one-step purification of forskolin
from a crude extract of Coleus forslohlii root [17].
Figure 3. Elution profile of P. ginseng crude extract separated by anti-G-Rb1 immunoaffinity column. The concentra‐
tion of G-Rb1 in each fraction was monitoring by ELISA using anti-G-Rb1 MAb. Individual fraction (2 mL) were assayed
by ELISA. aInhibition = (A0-A)/A0 ;A0 is the absorbance in the absence of the test compounds. A is the absence in the
presence the test compounds.
This methodology is effective for the rapid and simple purification of G-Rb1 and may open
up a wide field of comparable studies with other families of saponins for which an accepta‐
ble method for one-step separation has not yet been developed. Furthermore, to separate the
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total ginseng saponins, a wide cross-reactive MAb against ginsenoside, like anti G-Re MAb
which showed wide cross-reactivity, could be designed [34]. A combination of immunoaf‐
finity column, Eastern blotting and ELISA could be used to survey low concentrations of
ginsenoside Rb1 of plant origin and/or in experimental animals and human. In fact we have
succeeded in the isolation of G-Rb1 from a different plant, Kalopanax pictus Nakai, which was
not known previously to contain ginsenosides, using this combination of methods [35].
2.2.2. Isolation and determination of unknown compounds related to G-Rb1 by anti-G-Rb1
immunoaffinity column
Several species of ginseng are known to exist and contain different amount and kinds of gin‐
senosides. P. japonicus is distributed in Japan and China and it is morphologically different
from the other Panax species. Yahara et al. indicated that G-Rbl was not detected in P. japoni‐
cus, and isolated oleanane-type saponins called chikusetsusaponins and determined their
structures [36]. Morita et al. reported the varieties of saponins in P. japonicus by chemical
analysis. These results suggested that the concentration of G-Rb1 might be trace level in P.
japonicas [37]. We previously analyzed the G-Rb1 concentration in several ginseng roots by
ELISA using anti-G-Rb1 MAb and HPLC after pre-treatment under mildly alkaline condition
[32]. As shown in Table 1, G-Rb1 concentrationsof P. ginseng, P. notoginseng and P. quinquefo‐
lius were correlated between ELISA and HPLC. However, the G-Rb1 of P. japonicus was
higher concentrations compared with HPLC and previous reports [37]. This data suggest
that anti-G-Rb1 MAb using ELISA has the cross-reactivity with some unknown compounds
contained in P. japonicus.
G-Rb1 concentration
(µg/mg dry weight powder)
Sample ELISA HPLC
P. ginseng White ginseng 5.49 ±0.75 4.96 ± 0.05
Red ginseng 3.57 ± 0.62 3.93 ± 0.34
Fibrous ginseng 64.44 ± 3.64 69.75± 1.45
P. notoginseng 47.08 ± 3.34 42.39 ± 1.39
P. quinquefolium 48.51 ± 1.79 47.96 ± 1.04
P. japonicus 1.37 ± 0.34 0.63 ± 0.06
Table 1. G-Rb1 concentration in various ginseng samples
To clarify the unknown compounds bound to anti-G-Rb1 MAb, the crude extract of P. japoni‐
cus was concentrated by immunoaffinity column using anti-G-Rb1 MAb. The crude root ex‐
tract was loaded on the column and washed with the washing Buffer, followed by the
elution buffer as already indicated. Figure 4 shows the H2SO4 staining (A) and the Eastern
blotting (B) profiles of the washing fractions 1-4 and eluted fraction 5. Fraction 1 is first elut‐
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ed fraction by the washing buffer, and showed many spots, indicating chikusetsusaponins,
similar to the original extract of P. japonicus. After washing, the column was eluted by elu‐
tion buffer (fraction 5), and then one spot was detected. As shown in Figure 4B, Eastern blot‐
ting indicated two different spots in washing fraction (Compound 1) and eluted fraction
(Compound 2). These compounds bound with anti-G-Rb1 MAb have a dammarane saponin
having protopanaxadiol as a framework.
Figure 4. Purification and determination of ginsenosides of P. japonicus by the anti-G-Rb1 immunoaffinity column. TLC
(A) and Eastern blotting (B) profiles of the separated fractions from P. japonicus crude extract by the anti-G-Rb1 immu‐
noaffinity column. Lane S indicates the standard of ginsenosides (G-Rd, G-Rc, G-Rb1, G-Rg1, and G-Re). Lane 1-4 and
Lane 5 were the washing fractions and the eluted fraction, respectively.
Figure 5. Chemical structures of G-Rb1 and chikusetsusaponins purified from P. japonicus by the anti-G-Rb1 immunoaf‐
finity column.
Compound 1 has three sugar moieties in a molecule because that the R F value closes to that
of G-Rd, indicating that this compound is chikusetsusaponin III (Figure 5). Finally, we iden‐
tified that this compound as chikusetsusaponin III in a direct comparison with authentic
sample [32]. Another unknown spot, compound 2 appeared in fraction 5 of the eluted frac‐
tion. Thus, compound 2 has a similar molecular structure and high cross-reactivity with G-
Rb1, and seems to be related ginseng saponin having protopanaxadiol as an aglycone.
Moreover, compound 2 might have the same sugar fragments and possess five sugar moiety
compared with G-Rb1, as indicated by their R F value. From these evidences compound 2
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might be chikusetsusaponin III-20-O-gentiobiose, chikusetsusaponin VI (Figure 5), which
has 5 sugars in a molecule in good agreement with the R F value previously reported [38]
and we confirmed that compound 2 is chikusetsusaponin VI by the direct comparison with
authentic sample.
These data suggested that the anti-G-Rb1  immunoaffinity column could isolate some un‐
known structurally  resemble  compounds having cross-reactivity  against  anti-G-Rb1MAb.
Therefore,  this  purification system will  be applied to survey new compounds related to
target compound of MAb. In our previous studies, we demonstrated the immunoaffinity
purification against all solasodine glycosides from crude extract by one-step purification. In
this case, all solasodine glycoside have almost same cross-reactivity against anti-solamar‐
gine MAb [12].
2.2.3. Preparation of G-Rb1 knockout extract by anti-G-Rb1 immunoaffinity column
The capacity of this anti-G-Rb1immunoaffinity column is 20 µg of G-Rb1/ml gel [32]. By load‐
ing the samples not to exceed the binding capacity against G-Rb1, this immunoaffinity col‐
umn becomes possible to remove all G-Rb1 from crude ginseng extract. Figure 6 showed
H2SO4 staining of TLC of the purification steps by the immunoaffinity column. Lane 1 and 2
were spotted the standard of ginsenosides (G-Rd, G-Rc, G-Rb1, G-Rg1, and G-Re). Lane A, B,
and C were the crude extract, the washing fraction, and the eluted fraction, respectively. In
the crude extract (lane A), all spots of ginsenosides were clearly detected. On the other hand,
the washing fraction (lane B) contained all of the ginsenosides in the crude extract except G-
Rb1. Furthermore, the spot of G-Rb1 was detected in the eluted fractions (lane C). These data
strongly indicated that G-Rb1 molecule in the ginseng extract can be eliminated by an anti-
G-Rb1 immunoaffinity column and the washing fractions was knockout only by the antigen
molecule, G-Rb1. Thus, we named the washing fractions a knockout (KO) extract [39,40].
This KO extract may be useful for the determination of real pharmacologically active princi‐
ple in the TCMs.
Figure 6. Preparation of G-Rb1-KO extract from P. ginseng crude extract using anti-G-Rb1 immunoaffinity column.
Lane S1 and S2 indicate the standard of ginsenosides (G-Rd, G-Rc, G-Rb1, G-Rg1 and G-Re). Lane A, B, and C were the
crude extract, the washing fraction, and the eluted fraction, respectively.
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3. Glycyrrhizin-knockout extract and its application for in vitro assay
Licorice (Glycyrrhiza spp.) is also important crude drug used in over 70 % of the TCMs and
Japanese Kampo medicines. It is prescribed with other herbal medicines as a demulcent in
the treatment of sore throats, an expectorant for coughs and bronchial catarrh, an antitus‐
sive, a taste-modifying agent for relieving pain, an anti-inflammatory agent for anti-allergic
reactions, rheumatism and arthritis, a prophylactic for liver disease and tuberculosis and
adrenocorticoid insufficiency [41-43]. Accumulated evidence indicated that GC, a main sap‐
onin component of licorice, is one of the biologically active compounds. It has been reported
that GC exhibits numerous pharmacological effects such as anti-inflammation, anti-ulcer,
anti-tumor, anti-allergy, and hepatoprotective activities [44,45]. Clinically, GC has been used
to treat patients with chronic hepatitis [46,47]. Although GC is supposed to be a major active
principle in licorice crude extract, a number of studies by HPLC profiles suggested that lico‐
rice has many other bioactive components, including flavonoids, isoflavonoids and chal‐
cones [43,48]. Biological studies showed that various flavonoid glycosides and their
aglycones of licorice exhibit anti-inflammatory, anti-oxidative, anti-microbial, superoxide
scavenging, and anti-carcinogenic activities [43,48]. In order to confirm the role of GC in
TCM, we previously purified GC from TCM using an immunoaffinity column conjugated
with anti-GC MAb [20]. In this section, we describe the preparation of GC-KO extract and its
application for functional analysis of GC in licorice crude extract.
3.1. Preparation of GC-KO extract by anti-GC immunoaffinity column and the
characterization of GC-KO extract
Our previous study demonstrated the preparation of anti-GC MAb [11]. The cross-reactivi‐
ties of the anti-GC MAb against glycyrrhetic acid-3-O-glucuronide and glycyrrhetic acid
were 0.585 % and 1.865 %, respectively. The other related compounds (deoxycholic acid, ur‐
solic acid, and oleanolic acid) were all less than 0.005 %. Moreover, we established competi‐
tive ELISA and Eastern blotting method using anti-GC MAb [11,49].
The immunoaffinity column against GC was prepared by coupling the purified 60 mg of the
anti-GC MAb to 25 ml of an Affi-Gel Hz gel [11]. To eliminate GC from licorice extract, 12
mg of licorice crude extract (GC content: 1275.0 µg) in loading buffer (5 % MeOH) was ap‐
plied on the anti-GC MAb immunoaffinity column, and then the loading buffer was contin‐
uously circulated through the column to enhance the binding efficiency. After overnight
circulation at 4 °C, the unbound fraction was separated. The column was washed with
washing buffer (5 % MeOH) and then eluted with elution buffer (20 mM phosphate buffer
containing 30 % MeOH). After separation, each fraction was deionized and the solvent was
lyophilized. Figure 7 showed the recovery ratio of GC checked by ELISA. In the unbound
fraction, 3.50 µg of GC (0.27% of the applied GC) was detected. On the other hand, 1269.26
µg of GC (99.55% of the applied GC) was obtained in the bound fraction. These data indicate
that the anti-GC column could eliminate 99.55 % of the loading GC. Thus, we named this
unbound fraction “GC-knockout (GC-KO) extract” [50].
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Figure 7. Preparation of GC-KO extract from licorice extract by anti-GC immunoaffinity column.
To further characterize GC-KO extract,  the TLC analysis  and Eastern blotting were per‐
formed [50].  As shown in Figure 8A,  several  spots  including GC were detected in lico‐
rice  extract  (Lane  B).  However,  the  spot  of  GC was  completely  disappeared in  GC-KO
extract,  although all  other spots were clearly detected (lane C).  Eastern blotting by anti-
GC MAb indicated that  GC was detected in licorice extract  (Figure 8B,  lane B),  but  the
spot of GC was disappeared in GC-KO extract (Figure 8B, lane C). Therefore, these data
suggest that GC was specifically eliminated from licorice extract by anti-GC MAb immu‐
noaffinity column.
Figure 8. TLC profiles (A) and Eastern blotting by anti-GC MAb (B). Lane A, B, and C indicate GC, licorice extract, and
GC-KO extract, respectively.
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3.2. in vitro Assay by GC-KO extract prepared by anti-GC immunoaffinity column
Nitric oxide (NO), synthesized by NO synthase (NOS) from L-arginine, is an important reg‐
ulatory/modulatory mediator for several physiological processes [51]. However, during in‐
flammatory process, a large amount of NO is produced by inducible NOS (iNOS) stimulated
by bacterial lipopolysaccharide (LPS) and inflammatory cytokines participates in the patho‐
genesis of inflammatory diseases [52]. Overproduced NO synthesized by iNOS triggers a
variety of inflammatory diseases including sepsis, psoriasis, arthritis, multiple sclerosis, and
systemic lupus erythematosus [53]. Therefore, inhibiting NO production by blocking iNOS
expression may be useful strategy to treat a variety of inflammatory diseases.
In LPS-treated mouse RAW264 macrophages, licorice extract inhibited NO production and
iNOS expression. At 100 µg/mL of licorice extract, iNOS protein and mRNA were complete‐
ly suppressed [50].
Figure 9. Effect of GC-KO extract and the combination of GC-KO extract and GC on NO production (A) and iNOS pro‐
tein expression (B) in LPS-treated RAW264 cells.Each bar indicates the mean S.D. of four individual experiments.
*P<0.05, **P<0.01, ***P<0.001 indicate significant differences from the LPS alone
We next examined the inhibitory effect of GC alone, GC-KO extract and the combined treat‐
ment with GC and GC-KO extract on NO production [50]. Since 100 µg of licorice extract
contains 10.6 ±0.618 µg of GC,the cells were pre-treated with licorice extract (100 µg/ml),
GC-KO extract (89.4 µg/ml), or the combination of GC-KO extract (89.4 µg/ml) and GC (10.6
µg/ml). Figure9A indicated that the treatment of licorice extract led to a marked suppression
of NO production as compared to LPS treatment [inhibition ratio (IR) 57.7% ]. Interestingly,
the inhibitory effect of GC-KO extract was lower (IR 17.8% ) compared with licorice extract
although GC alone could not block NO production as indicated above. On the other hand,
the combined treatment with GC-KO extract and GC significantly improved the inhibitory
ability (IR 33.5% ). To determine whether the combinational effect of GC-KO extract and GC
was related to iNOS expression, we performed Western blotting. As shown in Figure 9B, the
treatment of GC-KO extract diminished the inhibitory ability of LE on iNOS expression, and
addition of GC to GC-KO extract could improve it. These data suggest that GC alone cannot
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suppress iNOS expression, but combinational inhibition of iNOS expression may occur
when GC coexists with the other constituents contained in licorice extract. The in vitro and in
vivo analysis by using KO extract prepared by immunoaffinity column is a useful approach
for determination of potential function of natural compound on in vitro and in vivo assays.
4. Conclusion
In this chapter,  we introduce the unique strategy of one-step purification of target com‐
pounds from crude extract by anti-natural compound specific MAb-conjugated immunoaf‐
finity column. The immunoaffinity column conjugated with anti-G-Rb1 MAb could purify
the G-Rb1  from P. ginseng  extract, and the washing fraction contained all compounds ex‐
pect only G-Rb1, which was named G-Rb1-KO extract. By the use of the cross-reactivity of
MAb, the anti-G-Rb1 immunoaffinity column can identify new unknown compounds relat‐
ed  to  target  compound  of  MAb  and  determine  their  structures.  Furthermore,  our  data
suggest  that  the  combination  of  the  immunoaffinity  column and ELISA by  using  MAb
provided a reliable and high sensitivity analysis for target compound in various TCMs and
crude extract. We also demonstrated the in vitro assay by using GC-KO extract prepared
by anti-GC immunoaffinity column from licorice extract.  The KO extract may be able to
support the pharmacological investigation for finding out a really active compound in a
TCM and crude drug.
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